There are still countries and regions in the world where the healthcare i...
Contribution by ONO to the SDGs We contribute to Goal 3, Goal ...
We have established a Sales Information Activities Supervisory Division w...
Governance Strategy Risk and opportunity management Indicators and...
In the Water Security survey conducted by CDP, a global environmental n...
We aim for highly transparent management, recognize the importance of ...
For more than 300 years since our foundation, we have walked han...
Risks and opportunities related to climate change are investigated under ...
In fiscal year 2025, ONO PHARMA TAIWAN supported the activities of ...
Even today as we see remarkable developments in the medical field, there ...
Collaboration with business partners is essential to reducing Scope 3...
Contributing to sustainable social development through business activit...
We cooperate with and hold seminars for citizens to raise awareness of ...
At Ono Pharmaceutical, the Board of Directors oversees important manageme...
Guided by its corporate philosophy, “Dedicated to the Fight aga...
In September 2023, ONO joined PSCI (Pharmaceutical Supply Chain I...
Our Approach to Human Rights In all its business activities in and out...
Basic policy The ONO Group will strive to maintain and ...
Support for Disease Prevention, Early Detection and Early Treatment ...
Scope 1+2 GHG emissions Reduction Roadmap ReducePromotion of e...
Water is an important resource for maintaining people's lives and health....
We have participated in Relay for Life (RFL) as a part of our social co...
We consider the collection of safety information regarding pharmaceutical...